Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

MAIA Biotechnology completed a $30 million equity raise and announced 2026 strategic milestones including Phase 3 trial progress for its ateganosine cancer therapy. The company secured FDA Fast Track designation and reported positive Phase 2 data showing median PFS of 5.6 months and OS of 17.8 months. Diamond Equity Research maintains a $10.27 per share valuation based on successful execution of clinical programs.

03/05/2026, 4:00 PM • GlobeNewswire

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock

MAIA Biotechnology, Inc. announced the successful closing of an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The offering was led by healthcare-dedicated investors alongside existing shareholders. The company plans to use net proceeds for clinical trials and general corporate purposes.

03/04/2026, 4:00 PM • GlobeNewswire

MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

MAIA Biotechnology priced an underwritten public offering of 20 million shares at $1.50 per share, raising $30 million in gross proceeds. The offering was led by healthcare-dedicated investors alongside existing shareholders. Net proceeds will be used for clinical trials and general corporate purposes. The offering is expected to close on March 4, 2026.

03/02/2026, 10:45 PM • GlobeNewswire

MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

MAIA Biotechnology announced an underwritten public offering of common stock and pre-funded warrants, with Konik Capital Partners LLC serving as sole book-running manager. The company intends to use net proceeds for clinical trials and general corporate purposes. MAIA's lead program, ateganosine (THIO), is a potential first-in-class cancer telomere targeting agent in clinical development for NSCLC treatment.

03/02/2026, 5:00 PM • GlobeNewswire

$207B Market Shift: The Race for Fast Track Approval in Oncology

The FDA has accelerated oncology drug approvals with over 50 approvals in 2025 and increased expedited designations in 2026. Multiple biotech companies are advancing cancer treatments through Fast Track and Breakthrough Therapy designations, targeting high-unmet-need solid tumors. Key developments include Oncolytics' pelareorep showing significant survival benefits in colorectal cancer, Relay's zovegalisib receiving Breakthrough designation for breast cancer, MAIA's ateganosine advancing in lung cancer, Zai Lab's AUGTYRO approval in China, and Arrivent's firmonertinib entering pivotal Phase 3 trials for NSCLC.

02/05/2026, 9:35 AM • Benzinga

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

MAIA Biotechnology is developing ateganosine, a novel telomere-targeting cancer therapy for non-small cell lung cancer patients who do not respond to existing treatments, with potential to address a significant unmet medical need.

12/10/2025, 2:00 PM • GlobeNewswire